
UN Report Estimates Hormone-Disrupting Chemicals Cost $1.1 Trillion a Year
File photograph · 10 September 2014: a US Environmental Protection Agency scientist inspects a water sample during work connected to screening chemicals for possible endocrine-disrupting effects. Photograph by Eric Vance for the US EPA, via Wikimedia Commons; US federal government public domain. Cropped for the web hero and adapted for the social card.
A new United Nations assessment says exposure to chemicals that interfere with hormones is producing health costs above $1.1 trillion a year, while only a small fraction of the chemicals and mixtures registered for use worldwide have been evaluated for endocrine-disrupting properties.
The 240-page assessment published Tuesday by the World Health Organization and the United Nations Environment Programme is the first major global update on endocrine-disrupting chemicals since 2012. It does not present one new experiment. It synthesizes more than a decade of research on exposure, health and wildlife effects, testing systems, regulation and the economic cost of inaction.
Endocrine-disrupting chemicals, or EDCs, can interfere with hormones that regulate development, reproduction, metabolism, immunity and other essential functions. Exposure can occur through food, water, air, skin contact and medical devices. The report says such chemicals have been detected in blood, breast milk and umbilical-cord blood, meaning exposure can begin before birth.
The evidence has strengthened most clearly around fertility and reproductive development, brain development and neurological function, thyroid regulation, metabolism, immunity and cardiovascular health. The assessment also identifies emerging concerns involving metabolic liver disease and possible kidney effects, while emphasizing that important scientific gaps remain. A chemical's presence in a product does not by itself establish the size of an individual person's risk; the identity, dose, timing and duration of exposure all matter.
The scale of the regulatory gap is nevertheless stark. More than 350,000 chemicals and chemical mixtures are registered for production and use globally, according to the report, but only a small fraction has been assessed for endocrine-disrupting properties. Regulatory systems also tend to examine substances one at a time even though people and ecosystems encounter mixtures.
The report's estimate of more than $1.1 trillion in annual health-related costs is described as conservative. It includes treatment expenses and lost productivity associated with selected exposures and health outcomes, but excludes additional damage to biodiversity, drinking water, food production and human rights. It is therefore a modeled estimate based on the evidence and assumptions surveyed by the authors—not a complete accounting of every illness or a bill that can be assigned to a single company or product.
That distinction matters because chemical manufacturers contest broader regulation. The American Chemistry Council told the Associated Press that existing national and regional frameworks are the best route for assessing risks from plastic additives. The plastics industry has also opposed writing new chemical restrictions into a global plastics treaty, arguing that existing conventions should regulate substances according to their uses.
But the present system places a large evidentiary burden on the public after exposure has already occurred. Testing a small share of a rapidly expanding chemical market, then regulating substance by substance, leaves workers, consumers and communities to absorb uncertainty while producers retain the commercial benefit. Replacing one known hazardous chemical with a closely related, poorly tested substitute can simply move the risk rather than remove it.
UNEP and WHO therefore call for stronger testing, monitoring, disclosure and regulation, with particular protection during pregnancy, infancy and childhood. Their joint release also points to food packaging, cosmetics, toys, textiles, healthcare, agriculture and waste as sectors where safer substitution and upstream controls are possible.
The political question is who pays for prevention and who pays when prevention fails. Pamphlets' recent reporting on toxic e-waste work in Ghana showed how hazardous exposure and cleanup costs are often pushed onto workers and communities far from the companies that design and profit from products. The same structure appears in the new assessment: private decisions about materials become public costs in hospitals, lost income and damaged ecosystems.
The science still contains uncertainty; that is not an argument for regulatory paralysis. When exposure is widespread, effects can begin before birth and only a small share of chemicals has been examined for hormonal disruption, waiting for perfect knowledge transfers the risk to the people with the least power to avoid it. The report's central demand is precaution backed by testing, disclosure and enforceable limits before harm becomes another externalized cost of production.




Comments